Tysabri (natalizumab) Market Report 2026

Tysabri (natalizumab) Market Overview

• The Tysabri (natalizumab) market growth in the historic period has been driven by increasing multiple sclerosis prevalence, approval of natalizumab therapy • Market expansion is supported by growth in ms diagnosis rates, improved infusion infrastructure • Growth Driver: Rising Prevalence of Autoimmune Disorders Drives Growth in the Tysabri Market • Market Trend: Tysabri Biosimilars Expands Treatment Options For Multiple Sclerosis • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Tysabri (natalizumab) Market?

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and nerve damage. Tysabri helps reduce the frequency of relapses and slow the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). The main indications for tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a disease that causes the breakdown of the protective covering of nerves. These are used for various patient settings such as inpatient, and outpatient, and are distributed by multiple distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Tysabri (natalizumab) Market Growth Forecast?

The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3.87 million in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in ms diagnosis rates, improved infusion infrastructure, enhanced risk mitigation programs, rising specialty neurology services, long-term clinical outcome support. Major trends in the forecast period include growing use of monoclonal antibodies in ms, preference for high efficacy disease modifying therapies, expansion of outpatient infusion care, improved safety and risk monitoring protocols, rising focus on progressive ms management.

Global Tysabri (natalizumab) Market Segmentation

1) By Clinical Indication: Multiple Sclerosis, Crohn's Disease 2) By Patient Setting: Inpatient, Outpatient 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Tysabri (natalizumab) Market?

The rise in the prevalence of autoimmune disorders is expected to propel the growth of the tysabri (natalizumab) market going forward. Autoimmune disorders are conditions where the immune system mistakenly attacks the body's own cells, tissues, or organs, causing inflammation and damage, leading to chronic conditions such as rheumatoid arthritis or multiple sclerosis, with causes involving a mix of genetic and environmental factors. The rise in the prevalence of autoimmune disorders is due to factors such as genetic predisposition, environmental triggers, and improved awareness and diagnosis, leading to more cases being identified. Tysabri is effective for autoimmune disorders as it targets specific immune cells, preventing them from causing inflammation and damage, which helps treat conditions such as multiple sclerosis and Crohn's disease. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are expected to be living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the rise in the prevalence of autoimmune disorders is driving growth in the tysabri (natalizumab) industry. Rising personalized medicine is expected to propel the growth of the tysabri (natalizumab) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rise of personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Tysabri (natalizumab) exemplifies the principles of personalized medicine by offering a targeted treatment approach for relapsing forms of multiple sclerosis, tailored to patients who exhibit specific disease activity and risk profiles, thereby maximizing therapeutic efficacy while minimizing potential adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Moreover, it includes seven drugs tailored for cancer treatment and three targeting different diseases and conditions. Therefore, rising personalized medicine drives the tysabri (natalizumab) industry.

Key Players In The Global Tysabri (natalizumab) Market

Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics

Global Tysabri (natalizumab) Market Trends and Insights

Major companies operating in the tysabri (natalizumab) market are focusing on expanding treatment options with alternative solutions, such as biosimilars, to provide patients with more effective therapies that improve quality of life and disease management. Biosimilars to Tysabri offer a cost-effective alternative for treating highly active relapsing-remitting multiple sclerosis, increasing access to essential treatment, especially in underserved regions. For instance, in January 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Tyruko (natalizumab), the first and only biosimilar to Tysabri, for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz's biosimilar portfolio and aims to improve access to effective and affordable treatments for people living with multiple sclerosis.

Regional Insights

North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tysabri (natalizumab) Market?

The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tysabri (natalizumab) Market Report 2026?

The tysabri (natalizumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tysabri (natalizumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.